Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).
Journal: JCO oncology practice
Published: March 06, 2026
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.
Journal: Breast cancer research and treatment
Published: November 22, 2025
Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.
Journal: NPJ breast cancer
Published: November 02, 2025
Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.
Journal: Breast (Edinburgh, Scotland)
Published: May 04, 2025
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.
Journal: Breast (Edinburgh, Scotland)
Published: January 15, 2025
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study.
Journal: Breast cancer research and treatment
Published: November 12, 2024
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer.
Journal: NPJ breast cancer
Published: April 08, 2024
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer.
Journal: NPJ breast cancer
Published: March 20, 2024
Last Updated: 09/26/2026